Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L29 pseudogene 26 (RPL29P26) is a processed, non-coding pseudogene related to the ribosomal protein L29 gene (RPL29). Pseudogenes like RPL29P26 do not encode functional proteins and are generally considered genomic relics without direct biological activity. RPL29P26 is listed as a pseudogene in genomic databases and does not participate in ribosome function, drug interactions, or recognized disease pathways. Pseudogenes are typically non-functional sequences in the genome, often resulting from duplication or retrotransposition events. They share high sequence homology with their functional counterpart genes but are unable to produce functional proteins because of disabling mutations (e.g., premature stop codons or frameshifts). RPL29P26 does not encode a functional protein and is therefore not considered a therapeutic target, receptor, enzyme, transporter, or functional cellular component. There are no known biological functions, disease roles, or therapeutic implications attributed to RPL29P26. It is not a biomarker, is not involved in drug interactions, and has no known associated safety concerns. RPL29P26 is not a functional gene product or therapeutic target, but a processed ribosomal pseudogene. There is nothing to suggest it is misspelled, but its inclusion as a biomedical target would be incorrect due to its lack of protein expression or direct biological function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L29 pseudogene 26 (RPL29P26).